

Accomplished Genomics Leader with extensive expertise in Life Sciences joins Zetta Genomics as Non-Executive Director

Zetta Genomics, leading innovator in Genomics data technology, proudly announces the appointment of Bram Goorden as Non-Executive Director to their Board.

CAMBRIDGE, CAMBRIDGESHIRE, UNITED KINGDOM, September 26, 2024 /EINPresswire.com/ -- Zetta Genomics, a leading innovator in the Genomics data technology space, proudly announces the appointment of Bram Goorden as Non-Executive Director to their Board. Bram is an accomplished Chief Executive Officer with over two decades of experience in the life sciences industry and joins to support the company's next phase of growth and transformation. With a rich background in scaling businesses, strategic operations, and maximising shareholder value, Bram brings a wealth of expertise that aligns with Zetta Genomics' mission.



Bram Goorden, Non-Executive Director, Zetta Genomics



Transformational Leadership in Life Sciences

Bram's diverse career in the life sciences spans NCEs, in vitro diagnostics, and multi-omics SaaS and AI solutions. He has successfully led both early- and late-stage organisations, driving IPOs, global operations, and strategic alliances with industry leaders like GE Healthcare, AstraZeneca, and Roche.

Proven Expertise in Global Expansion

Currently CEO at IXICO plc, a London based precision medicine company in neurodegenerative diseases, Bram previously scaled Eagle Genomics' microbiome AI platform and helped SOPHiA Genetics achieve revenue growth leading up to a \$1.1B IPO. At Foundation Medicine, he led



I am proud to bring my experience and expertise to contribute to Zetta Genomic's vital mission and advance the future of precision medicine."

Bram Goorden

international expansion across 60+ countries, advancing biomarker and oncology research and BioPharma development efforts.

Driving Innovation and Patient-Centric Partnerships

Bram is highly experienced in forming strategic partnerships that drive scientific innovation.

Bram's leadership has consistently focused on improving patient outcomes, navigating regulatory challenges, and delivering transformative healthcare solutions. His efforts

have led to key product launches in diverse geographies, including the US, Europe, China and Japan.

Brams says ; "As genomic sequencing becomes increasingly cost-efficient, the next significant challenge is effectively managing and leveraging vast genomic data to transform healthcare. Zetta Genomics' platform plays a critical role in addressing this challenge. I am proud to bring my experience and expertise to contribute to this vital mission and advance the future of precision medicine."

'We are excited to welcome Bram to the Zetta Genomics Board' says CEO and Founder Ignacio Medina, 'His vast experience in life sciences and demonstrated ability to scale organisations will be instrumental as we continue to grow and expand our global footprint.'

Kate Melsom-John

Zetta Genomics Ltd

+44 1223 690140

kate.melsom@zettagenomics.com

Visit us on social media:

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/746399047>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.